An observational study in Traumatic Brain Injury, Subarachnoid Hemorrhage and Brain Injuries, sponsored by CHU de Quebec-Universite Laval. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-18.
Sponsored by CHU de Quebec-Universite Laval · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies in Brain Injuries, Traumatic with a site in Canada — 20 open to participants now, 22 under way, 2 of them phase 3. Brain Injuries, Traumatic · Canada.
Among the 69 studies in Brain Injuries, Traumatic with a site in Canada, this one is the 6th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2021, is one of 18 observational ones, reaches primary completion later than 1 of the 21 other live ones, and was the 55th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →20 of the 69 studies in Brain Injuries, Traumatic with a site in Canada are open now. Recruiting first, the newest first:
Columbia University · Sites in Canada, United States, Brazil and 2 more countries
Ages 18+
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–70
D.J Cook · Sites in Canada
Ages 18+
University of Calgary · Sites in Canada
Ages 18–70 · Healthy volunteers
University of Alberta · Sites in Canada
Ages 4–17
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 9 · Phase 4 2
First in 2003; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 286 is above the median of 116 across 558 observational studies indexed under Brain Injuries, Traumatic.
Median enrollment 70 across the 51 interventional studies, 135 across the 18 observational. Of the 30 that completed or were terminated, 5 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 69 have an industry lead sponsor. The 10 most frequent:
CHU de Quebec-Universite Laval is the lead sponsor of 137 studies on the registry; 27 are open to participants now.
CHU de Quebec-Universite Laval has 4 studies filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
5 of the studies in Brain Injuries, Traumatic with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03559114Phase 3Sunnybrook Health Sciences CentrePROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST) | 2026-12 |
| NCT07090057University of AlbertaThe Effect of Targeting the Plantaris Muscle-tendon in Surgical Correction of Ankle Equinus in Children | 2026-12-31 |
| NCT05897593University of AlbertaClinical Feasibility & Validation of the Augmented Reality GlenxRose Acquired Brain Injury Rehabilitation Programs | 2027-05-31 |
| NCT04855396University of MichiganThe Biomarkers in the Hyperbaric Oxygen Brain Injury Treatment Trial (BioHOBIT) | 2027-07-31 |
| NCT03754114University of MichiganBrain Oxygen Optimization in Severe TBI, Phase 3 | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies in Brain Injuries, Traumatic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The NeurO2 study is a multicenter observational study looking at NIRS monitoring in neurocrocritically ill patients during the acute phase of care following an acute brain injury. The study is nested within the HEMOTION Trial and the SAHaRA Trial
The NeurO2 study is a multicenter prospective study nested within two large-scale pragmatic randomized open blinded endpoint (PROBE) trials in neurocritically ill patients, the HEMOTION and the SAHaRa trials. These two trials are designed to compare a restrictive and a liberal transfusion strategies in critically ill patients with traumatic brain injury or subarachnoid hemorrhage. The NeurO2 will report on prospectively gathered regional cerebral oxygenation data (rSO2) from enrolled patients randomized to either the liberal or restrictive RBC transfusion strategy of their parent trials. The primary outcome will be 6-month neurologic function based on the GOSe. The established infrastructure of the trials will be used, including part of the data collection instruments and the outcome assessment team.
The NeurO2 study will achieve three separate but interconnected primary objectives: i) Evaluate if the cerebral hypoxemic burden as measured by NIRS during NICU stay, is associated with functional neurologic outcome (Glasgow Outcome Scale extended - GOSe) at 6 months, ii) Determine if the cerebral hypoxemic burden is impacted by red blood cell transfusion, iii) Determine if the level of response in cerebral hypoxemic burden after RBC transfusion is associated with the 6-month functional neurologic outcome (GOSe)
The secondary objectives are to evaluate whether the cerebral hypoxemic burden measured by NIRS is associated with other clinically relevant outcomes including ICU, hospital and 6-month mortality and hospital, ICU length of stay and quality of life.
Adult patients hospitalized with a traumatic brain injury or with aneurysmal subarachnoid hemorrhage already enrolled in the HEMOTION Trial or the SAHaRA Trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.
Glasgow Outcome Scale extended
The GOSe is an ordinal scale on 8 points evaluating the neurological functional outcome in neurocritically ill patients where 1 represents death and 8 the best possible outcome.
Time frame: 6 months
Mortality
Incidence of mortality
Time frame: 6 months
Hospital length of stay
Duration of hospital stay for the index hospitalisation
Time frame: through study completion, an average of 6 months
ICU length of stay
Duration of intensive care unit (ICU) stay for the index hospitalisation
Time frame: through study completion, an average of 6 months
EQ-5D-5L
EQ-5D-5L is a standardised measure of health-related quality of life developed by the EuroQol Group. The EQ-5D-5L includes a 5-dimension questionnaire and an overall health question using a visual analogue scale (VAS). The 5 dimensions of the EQ-5D-5L are mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is evaluated based on 5 levels (from the worst (1) to the best (5)). The overall health evaluation is based on a 100 point VAS where 100 means the optimal health
Time frame: 6 months
Plan to share: Undecided — To be determined
No publications or documents are linked to this record.
Started May 2021 (actual). Primary completion is estimated for Jul 2024, 38 months after the start.
Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 38 months is below that.
Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CHU de Quebec-Universite Laval →